Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021

Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged 16 years (4). Prelicensure randomized trials in persons aged 5 years documented high vaccine efficacy and immunogenicity (5), and real-world studies in persons aged 12-18 years demonstrated high vaccine…

• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• BD
  BioFire Diagnostics
• S
  Seqirus
• NI
  National Institutes of Health
• G
  Genentech
• NI
  National Institute of Allergy and Infectious Diseases
• NI
  National Institute of Child Health and Human Development
• DO
  Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases